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Pancreatic endocrine tumorsForegut neuroendocrine tumors [NETs] usually pursuit a benign course, but some show aggressive behavior.
The treatment of patients with advanced NETs is marginally effective and new approaches are needed. In
other tumors, transactivation of the EGF receptor (EGFR) by growth factors, gastrointestinal (GI) hormones
and lipids can stimulate growth, which has led to new treatments. Recent studies show a direct correlation
between NET malignancy and EGFR expression, EGFR inhibition decreases basal NET growth and an autocrine
growth effect exerted by GI hormones, for some NETs. To determine if GI hormones can stimulate NET growth
by inducing transactivation of EGFR, we examined the ability of EGF, TGFα and various GI hormones to
stimulate growth of the human foregut carcinoid,BON, the somatostatinoma QGP-1 and the rat islet tumor,
Rin-14B-cell lines. The EGFR tyrosine-kinase inhibitor, AG1478 strongly inhibited EGF and the GI hormones
stimulated cell growth, both in BON and QGP-1 cells. In all the three neuroendocrine cell lines studied, we
found EGF, TGFα and the other growth-stimulating GI hormones increased Tyr1068 EGFR phosphorylation.
In BON cells, both the GI hormones neurotensin and a bombesin analogue caused a time- and dose-
dependent increase in EGFR phosphorylation, which was strongly inhibited by AG1478. Moreover, we
found this stimulated phosphorylation was dependent on Src kinases, PKCs, matrix metalloproteinase
activation and the generation of reactive oxygen species. These results raise the possibility that disruption
of this signaling cascade by either EGFR inhibition alone or combined with receptor antagonists may be a
novel therapeutic approach for treatment of foregut NETs/PETs.
Published by Elsevier B.V.1. Introduction
Foregut neuroendocrine tumors (NETs)/pancreatic endocrine tumors
(PETs) originate from the neuroendocrine cells of the diffuse endocrine
system of the stomach, lung, ﬁrst part of duodenum and pancreas
[1,2]. Although these tumors have been considered rare, their
incidence is increasing [2]. They are classiﬁed either on a clinical
basis, depending on the presence of hormone hypersecretion (func-
tioning vs. non-functioning), their grade of differentiation (well
vs. poorly differentiated) or location of the primary lesion [2].factor receptor; GI, gastrointes-
d neck squamous cell cancers;
tumors; NT, neurotensin; PETs,
te cyclase activating peptide;
α, Transforming growth factor
esearch Program of the NIDDK,
m 9C103, Bethesda, MD 20814,
nsen).
.V.Overall, foregut NETs/PETs display a common secretory system
and physiological response (production and/or secretion of neural/
hormonal regulators), with a heterogeneous clinical presentation
at diagnosis [3,4]. Although in some cases they present with a
hypersecretion syndrome and show a relative slow growth rate, a
subset show more aggressive growth. At present 60–80% of cases
are diagnosed at advanced stages, with metastases [1,3]. The only
effective approach is surgical resection, but it is possible in only
10–20% [3,4]. Other treatments for patients with advanced foregut
NETs/PETs include the use of kinase inhibitors, peptide-radioligand
therapies, biotherapy (interferon,somatostatin and chemotherapy)
[1,2,5,6], but inmost cases the survival rates remain low [1]. For this rea-
son there is a need for new therapeutic approaches [5–7].
Growth factors and their receptors play an important role in con-
trolling cell growth, differentiation and migration and this represents
a key component in tumor development and growth [7,8]. Epidermal
growth factor (EGF) and its receptor (EGFR) are frequently over-
expressed by tumors [8]; including foregut NETs/PETs [9–12], espe-
cially in the most aggressive forms. In vitro studies on carcinoids
and PET cell lines demonstrate that activation of the EGFR receptor
can stimulate stimulate growth and that its inhibition can inhibit
basal growth [11,13,14].
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is transactivation of EGFR by the activation of G protein-coupled
receptors (GPCRs), generally by gastrointestinal (GI) hormones/
neurotransmitters or other biologically active substances, such as prosta-
glandins and lipids [15–17]. The abnormal secretion, either autocrine or
paracrine of these substances in tumors, leads to the activation of GPCRs,
which, in turn, transactivate EGFR [15,16,18]. This occurs in a number of
cancers [head/neck squamous cell carcinoma (HNSCC) [16], lung, pros-
tate, breast, colon] as well various endocrine cancers and those of other
tissues [15,17–21]. AmongGI hormones/neurotransmitters, neurotensin,
bombesin-related peptides, bradykinin, gastrin and PACAP are known to
play an important role in controlling tumor growth by transactivation of
EGFR in a number of cancers [17–23].
It is reported that a number of GI hormones/neurotransmitters can
affect the growth of neuroendocrine tumors [7,24]. Even though it has
been shown that activaton of EGFR can alter the basal growth of NETs
[11,13,14], it is unknown whether EGFR-transactivation is involved in
the stimulation by GI hormones/neurotransmitters of their growth or
if so, the cellular mechanisms involved.
Therefore the aim of this study was to address these issues by inves-
tigating the ability of GI hormones/neurotransmitters to stimulate the
growth of various foregut neuroendocrine tumor cell lines anddetermin-
ing whether transactivation of EGFR was important in mediating this
growth effect and if so, deﬁne the celluar signaling cascades involved.
2. Materials and methods
2.1. Materials
Dulbecco'sminimumessentialmedium(DMEM), phosphate-buffered
saline (PBS), fetal bovine serum (FBS), were from Invitrogen (Carlsbad,
CA); Thymidine, [6-3H], >97%, 1 mCi (37 MBq) from Perkin Elmer (Bos-
ton, MA); Tris buffered saline (TBS) from Cellgro® (Mediatech Inc.
Manassas, Va); Dimethyl sulfoxide (DMSO), trichloroacetic Acid (TCA),
MTT (3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide),
DL-dithiothreitol (DTT), phenylmethylsulfonyl ﬂuoride (PMSF), Tiron
and N-Acetyl-cysteine were from Sigma–Aldrich (St. Louis, MO);
HumanEGF (Recombinant, E. coli), PACAP27, the tyrosine kinase inhibitor
AG178, the Src family kinases inhibitor PP2 and PP3, GF 109203X and GM
6001 were from Calbiochem (San Diego, Ca). TGFα BioVision (Mountain
View, Ca), neurotensin and bradykinin were from Bachem (Torrence,
CA); the bombesin analogue, [DTyr6, βAla11,Phe13,Nle14]Bn [(6–14)]
obtained fromDr. DavidH. Coy, TulaneUniversity (NewOrleans, La); pro-
tease inhibitor tablets were from Roche (Basel, Switzerland); α-tubulin
and phospho-EGF receptor (Tyr1068) antibodies and non-fat dry milk
were from Cell Signaling Technology, Inc. (Beverly, MA) and horseradish
peroxidase (HRP)-conjugated secondary antibody (anti-rabbit) and




The metastatic human pancreatic carcinoid cell line, BON was
obtained from Cancer Research UK Cell Services and grown in
DMEM/F12K (1:1), with 10% FBS and supplemented with penicillin/
streptomycin. The human somatostatinoma cell line, QGP-1, was
obtained from Cancer Research UK Cell Services and the rat islet cell
tumor, Rin-14B was obtained from ATCC (Manassas, VA). Both cell
lines were grown in RPMI with 10% FBS and supplemented with
penicillin/streptomycin. The cells were mycoplasma free and incubat-
ed at 37 °C in 5% CO2/95% air.
2.2.2. Western blotting
Brieﬂy, after adding lysis buffer [50 mM Tris/HCl (pH 7.5),
150 mM NaCl, 1% Triton X-100, 1% deoxycholate, 0.1% sodiumazide, 1 mM EGTA, 0.4 mM EDTA, 1 mM DTT, 0.4 mM sodium
orthovanadate, 1 mM PMSF, and one protease inhibitor tablet per
10 ml], lysates were sonicated, centrifuged at 13,000 rpm for
20 min at 4 °C and protein concentration was measured using the
Bio-Rad protein assay reagent (Hercules, CA). Equal amounts of
protein from lysates were loaded on to SDS-PAGE using 4–20%
Tris-Glycine gels Invitrogen (Carlsbad, Ca). After electrophoresis,
proteins were transferred to nitrocellulose membranes overnight.
Membranes were washed twice in washing buffer (TBS plus 0.1%
Tween®20), at room temperature for 1 h, and then incubated with
primary antibody at 1:1000 dilution in washing buffer+5% BSA
[Phospho-EGFR (Tyr1068) or tubulin, as loading control] overnight at
4 °C. Then, membranes were washed twice in blocking buffer (TBS,
0.1% Tween® 20, 5% non-fat dry milk) for 4 min and then incubated
with HRP-conjugated secondary antibody (anti-rabbit) for 1 h at
room temperature. Membranes were washed again twice in blocking
buffer for 4 min, and then twice in washing buffer for 4 min followed
by incubation with chemiluminescence detection reagents for 4 min
and ﬁnally were exposed to Kodak Biomax ﬁlm (MR, MS). The inten-
sity of the protein bands was measured using Kodak ID Image
Analysis.
2.2.3. [3H]-Thymidine uptake
BON (1.5×105 cells/well) and QGP-1 (4×104 cells/well) cells
were plated in 24-well plates in DMEM/F12K with 10% FBS or RPMI
with 10% FBS, respectively. After 24 h cells were washed twice with
PBS and starved in DMEM/F12K or RPMI without FBS, for additional
24 h. Then, peptides and hormones were added for 24 h. Six hours
before the end of the incubation 1 μCi/ml of [3H]-Thymidine was
added to each well. Then cells were washed 3 times with 1 ml iced
cold PBS and incubated with 1 ml of ice cold 5% TCA at 4 °C for
30 min. After that, TCA was aspirated and cells were washed twice
with iced cold PBS. Finally, cells were resuspended in 0.5 ml of
0.5 N NaOH/0.5% SDS and placed in a scintillation vial and counted
in a scintillation counter.
2.2.4. MTT assay
5×103 BON cells were seeded in 96-well plates and incubated for
24 h in 100 ml of DMEM/F12K with 10% FBS. Then, cells were washed
twice in PBS and the starvation media (DMEM/F12K) with peptides
and hormones were added for 24 h. Three hours before the end of
the treatments 10 ml of MTT (1.2 mM, ﬁnal concentration) was
added to each well; after 3 h, 50 ml of 0.04 N HCl in isopropanol
was added to each well and incubated at room temperature for
5 min. The plate was read at 595 nm using a microplate reader.
2.2.5. Statistical analysis
All results are expressed as mean±SEM from at least 3 experi-
ments, and results were considered signiﬁcant if, in a paired t-Test
and in one-way ANOVA (Dunnett's multiple tests, as a post test), p
wasb0.05. PRISM GraphPad software (GraphPad Software Inc., La
Jolla, CA) was used for all statistical analysis.
3. Results
3.1. Ability of EGF, TGFα or various GI hormones to stimulate growth of
BON and QGP-1 cells and effect of an EGFR inhibitor, AG1478
To assess the effect of GI hormones on BON cell line growth, we
performed two different assays, the MTT assay (Fig. 1A) and an as-
sessment of [3H]-Thymidine uptake (Fig. 1B). EGF and TGFα stimulat-
ed BON cells growth by 30% and 40% in the MTT assay, respectively.
With [3H]-Thymidine assessment, growth stimulated by EGF or
TGFα was 32% and 42%, and was 180% with the addition of 10%
fetal bovine serum. With both experimental approaches, each GI
hormone/neurotransmitter [a bombesin analogue (Bn-analogue),
Fig. 1. Effect of the EGFR inhibitor, AG1478 on growth of BON and QGP-1 neuroendo-
crine tumor cells stimulated by EGF, TGFα and various GI hormones. BON and QGP-1
cells were incubated for 24 h, in serum-free medium, either with EGF, TGFα or the in-
dicated GI hormones, at the indicated concentrations, in the presence or in the absence
of the EGFR inhibitor, AG1478 (1 μM). Cell growth was evaluated by either an MTT
assay (A) or measuring [3H]-Thymidine uptake (B) for BON cells, and measuring
[3H]-Thymidine uptake for QGP-1 cells (C). **pb0.01 stimulants vs. control; +pb0.01
stimulants vs. AG1478 co-treatment. Results are mean±SEM from 6 experiments.
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20–30. In contrast, treatment with the hormones galanin and CCK/
gastrin, did not exert any effect on cell growth (data not shown). To
assess if the cell growth induced by the GI hormones required EGFR
activation, we pre-treated BON cells with the EGFR tyrosine kinaseinhibitor AG1478 (1 μM) (Fig. 1A, B). The stimulation of cell prolifer-
ation induced by each GI hormone was completely inhibited by
AG1478 pre-treatment, as was the stimulation of growth by EGF or
TGFα. In the somatostatinoma cell line QGP-1, the growth factor
TGFα as well as the GI hormones NT and a Bn-Analogue, stimulated
cell growth, in an EGFR-dependent way, determined by assessing
[3H]-Thymidine incorporation (Fig. 1C).
3.2. Ability of EGF, TGFα or the GI hormones to stimulate EGFR tyrosine
phosphorylation in NET cell lines
To directly assess the ability of GI hormones to transactivate the
EGFR in BON cells, we analyzed, by Western blotting, Y1068 phosphor-
ylation of EGFR, which correlates with EGFR activation [25]. BON cells
treated with EGF (16 nM), TGFα (3.6 nM), NT (1 μM), Bn-analogue
(1 μM), PACAP (1 μM) or bradykinin (1 μM) for 30 min (Fig. 2A, B),
as well as with EGF or TGFα, signiﬁcantly stimulated Y1068 EGFR
phosphorylation (Fig. 2A, B). To examine this in more detail, we stud-
ied the effect of the EGFR tyrosine kinase inhibitor, AG1478 on stim-
ulation of Tyr1068 phosphorylation by EGF or by two GI hormones
[NT or a Bn-analogue]. AG1478 (1 μM) inhibited EGF stimulation by
88% and inhibited completely Y1068 EGFR phosphorylation, stimulat-
ed by the Bn-analogue or by NT in BON cells (Fig. 2C, D).
To assess if the effect of GI hormones to stimulate EGFR phosphor-
ylation was seen in other foregut NET/PET cell lines, we performed
the same experiment, on the human somatostatinoma QGP-1 cell
line and on the rat islet cell tumor, Rin-14B. As showed in Fig. 2, in
QGP-1 (Fig. 2E,F) and in Rin-14B (Fig. 2G, H), the GI hormones,
Bn-analogue (1 μM), NT (1 μM) and PACAP (1 μM) as well as the
growth factor, EGF (16 nM) are able to stimulate the Y1068 EGFR
phosphorylation. This stimulation is reversed, in each case, by
AG1478 (1 μM) pre-treatment.
3.3. Time-dependent and dose-dependent EGFR phosphorylation induced
by Bn-analogue and NT
Next, we investigated, in more detail, the ability of EGF,
Bn-analogue and NT to stimulate Y1068 EGFR phosphorylation in
BON cells. EGF treatment caused a rapid phosphorylation in Y1068
EGFR, with a t1/2 at 3 min (Fig. 3A, B). Conversely, the Bn-analogue
(Fig. 3C, D) and NT (data not shown) induced a slower time-
dependent EGFR phosphorylation, reaching a 3.4-fold increase at
62 min with a t1/2=12 min, followed by a decrease in stimulation
with the Bn-Analogue. Moreover, we evaluated the increase of EGFR
phosphorylation in response to increasing doses of Bn-analogue
(Fig. 3E, F) or NT (Fig. 3G, H). EGFR Y1068 phosphorylation increased
with increasing GI hormone concentration reaching a 2.4-fold in-
crease with 1 μM Bn-analogue (EC50=17±2.2 nM) (Fig. 3F) and a
2.6-fold increase with 1 μM NT (EC50=0.44±0.08 nM) (Fig. 3H).
3.4. Src kinases mediate the EGFR-transactivation induced by
Bn-analogue and NT in BON cells
To further explore the cellular pathways that mediate EGFR-
transactivation induced by Bn-analogue and NT, we studied the effect
of the Src kinase inhibitor,PP2 on Y1068 EGFR phosphorylation induced
either by Bn-analogue or NT. BON cells pre-treated with 10 μMPP2, but
not PP3, an inactive PP2 analogue, strongly reduced Y1068 EGFR phos-
phorylation stimulated by Bn-analogue (Fig. 4A, B) or NT (Fig. 4A, C).
3.5. PKC and matrix metalloproteinases (MMPs) activation are involved
in Bn-analogue and NT induced EGFR-transactivation
To determine whether EGFR-transactivation by Bn-analogue and
NT is mediated by PKC activity, BON cells where pre-treatment
with the PKC inhibitor, GF 109203X. EGFR Y1068 phosphorylation
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strongly inhibited (86% and 77%, respectively) by GF 109203X
pre-treatment (compare in Fig. 5A, lanes 2,4 to Fig. 5C, lanes 5, 6).
To investigate the ability of Bn-analogue and NT to possibly induce
EGFR-transactivation through activation of MMPs leading to cleavage
of an EGF-related peptide, as demonstrated in other systems [19], we
pre-treated BON cells with the MMP inhibitor, GM 6001. Inhibition of
MMPs activity, by GM 6001, reduced the EGFR Y1068 phosphorylation
stimulated either by Bn-analogue (Fig. 5A, B) or NT (Fig. 5C, D) by 75%
and 60%, respectively (compare in Fig. 5A, lanes 2,3 and in Fig. 5C,
lanes 2, 3).
3.6. Production of reactive oxygen species (ROS) is involved in
Bn-analogue and NT induced EGFR-transactivation in BON cells
In some cells the generation of ROS is required for various
stimulants to cause EGFR-transactivation [19,21,26]. To determine if
the generation of ROS was involved in EGFR-transactivation by
Bn-analogue and NT, we pre-treated BON cells with the antioxidant,
N-acetylcysteine (NAC) or Tiron, a superoxide scavenger [19]. EGFR
Y1068 phosphorylation stimulated by the Bn-analogue (Fig. 6A, B) or
NT (Fig. 6C, D) were strongly impaired by both antioxidants pre-
treatment, by 85% for Bn-analogue (in Fig. 6A compares lanes 2, 3, 4)
and by 37–45%, for NT (in Fig. 6C, compare lanes 2, 3, 4).
4. Discussion
The aim of this study was to examine the role of EGF receptor
transactivation in mediating the ability of gastrointestinal hormone/
neurotransmitters to stimulate growth of Foregut NET/PETs. This
study was undertaken for a number of reasons.
Foregut NETs/PETs represent a heterogeneous group of tumors
whose incidence has increased in the last 30 years [2,4]. Although
generally slow growing, 60–80% of cases are diagnosed with meta-
static disease, and a proportion is rapidly growing causing death
[1,2,5]. The only curative treatment is surgery, but this is frequently
limited due to metastatic spread and in general, current treatment
of most patients with advanced metastatic disease is unsatisfactory
[3]. Current approaches include the use of tyrosine kinase and
mTOR inhibitors, peptide radio-receptor therapies, chemotherapy,
biotherapy (somatostatin, interferon) and local ablative treatments
of the metastatic disease [1,2,5]. None of these, generally, results in
a complete response and they generally show an incomplete response
with a 5-year survival rates at 20–40% [1]. Therefore, there is a need
for new treatment approaches [1,3,4].
The importance of growth factors and their cognate receptors
in tumor growth, differentiation and invasion is fully established in a
number of tumors [8]. Several growth factors and/or their receptors
are reported in various Foregut NETs/PETs, as well as frequently over-
or ectopically-expressed and to show gene ampliﬁcation [9–12]. They
include insulin-growth factor I (IGFI) [12]; platelet derived growth
factor (PDGF) [14] and EGF/TGFα [27]. In some Foregut NETs/PETs,
EGF/EGFR appears to be particularly important in growth as an auto-
crine growth factor [9,10,12,27,28]. Furthermore, a direct correlation
between EGFR expression and malignant behavior is reported and can
result in activation of growth cascades, involving AKT and MAPK [29].
In the rat insulinoma cell lines, epiregulin, an EGFR ligand, stimulates
cell growth [30] and in the enterochromafﬁn (EC) cell line KRJ-I, TGFαFig. 2. Ability of EGF, TGFα or various GI hormones to stimulate EGFR tyrosine 1068 phosph
QGP-1 and Rin-14B neuroendocrine tumor cells (Panels E–H). Left panels (Panels A, C, E, G)
cated NET cells treated for 30 min with EGF, TGFα or the various GI hormones at the indi
(Panels B,D,F,H) show the results of the densitometric analysis of the stimulation of EGFR
cells. Shown are means±SEM from 4 separate experiments **pb0.01; *pb0.05 vs. no AG14and TGFβ increase cell growth [13]. Moreover, in the ileal carcinoid
cell line, HC45, and in the rectal carcinoid cell line HC49, EGFR and its
activated/phosphorylated form are found, and treatment with an
EGFR kinase inhibitor reduces cell proliferation [14].
One of the most frequently used mechanisms for growth involving
EGFR, besides overexpression, mutation and ampliﬁcation, is EGFR-
transactivation [15,16,31]. EGFR-transactivation is most frequently
due to activation of various G protein-coupled receptors (GPCRs)
[16], frequently due to ectopic autocrine secretion, and the release
from other sites, of GI hormones/neurotransmitters, or to the release
of other biologically active substances (bioactive lipids, prostaglan-
dins, etc.) [15]. This mechanism occurs in a number of common
tumors, including prostate, lung, breast, colon and head and neck
squamous cell carcinoma (HNSCC) [16,17,32]. In lung cancer, cell pro-
liferation is increased by transactivating EGFR due to the activity of
bombesin-related peptides [19–21] and pituitary adenylate cyclase
activating polypeptide (PACAP) [17]. The cross-talk between these
two pathways is complex and frequently involves second messen-
gers, including changes in intracellular Ca+2, activation of protein ki-
nase C (PKC), adenylate cyclase, generation of reactive oxygen species
(ROS), activation of non-receptor tyrosine kinases, such as Src, and
the activity of matrix metalloproteinases (MMPs) [16].
GI hormones/neurotransmitter GPCRs are present in Foregut
NETs/PETs and can effect cell proliferation [24]. Somatostatin recep-
tors are highly expressed and homogenously distributed in these tu-
mors [34–36], as well as receptors for VIP, gastrin/cholecystokinin
(CCK) [24], secretin [36], PACAP and mammalian bombesin receptors
(GRPR, NMBR). Although numerous studies have been performed to
assess the effect of GI hormones/neurotransmitters on growth of var-
ious cancers [15], few studies have focused on their effect in Foregut
NETs/PETs proliferation [13,38–42]. Somatostatin receptor agonists
reduce growth of a number of NETs [3,36,43,44], as well as antago-
nists of CCK2R inhibit gastric carcinoid tumor growth [42]. In the EC
cell line, KRJ-I cell line and in the broncho-pulmonary NET cell line,
NCH720, serotonin stimulates cell proliferation and the synthesis of
several growth factors [41]. In no cases were the role and the mecha-
nism of EGFR-transactivation in mediating these growth effects
explored.
To address this question, in this study, the role of EGFR-transactivation
in growth control by various GI hormones/neurotransmitters, was evalu-
ated in a number of Foregut NET/PET cell lines [BON, QGP-1, Rin-14B
cells] and detailed mechanistic studies were performed on BON cells.
BONcells, are derived froma lymph nodemetastasis of a pancreatic neu-
roendocrine carcinoid tumor and resemble both foregut and midgut
characteristics [45]. Previous studies have shown that treatment of
the BON cells with EGF, as well as with other growth factors and GI
hormones/neurotransmitters, like PACAP, stimulates cell proliferation.
Moreover, treatment with Geﬁtinib (Iressa, Astra Zeneca) or AG1478,
inhibitors of EGFR [31], completely blocks BON cell basal proliferation
and induces apoptosis [11]. Among the substances synthesized and
secreted, BON cells produce serotonin and several peptides such as
neurotensin (NT) and bombesin [45] and display high bombesin recep-
tor (GRPR, BRS-3) and high VIP receptor (VPAC1) densities, as well
as for somatostatin receptors (sst1, 2, 5) [43,46].To conﬁrm our results
of the importance of EGFR trasactivation in BON cells and establish as
it a common mechanism occurring in neuroendocrine tumors, we also
evaluated the effect of GI hormones/neurotransmitters in other two
Foregut NET/PET cell lines: the human somatostatinoma QGP-1 and
the rat islet cell tumor Rin-14B.orylation and the effect of the EGFR inhibitor, AG1478 in BON cells (Panels A-D) and in
show representative Western blot analysis of EGFR Y1068 phosphorylation of the indi-
cated concentrations (these experiments are representative of 4 others). Right panels
Y1068 phosphorylation shown in the corresponding left panel for the indicated NET
78.
Fig. 3. Time courses (Panels A–D) of EGFR Tyrosine 1068 phosphorylation stimulation (EGF, the Bn-analogue) and dose–response stimulation (Panels E–H) (NT, the Bn-analogue) in
BON cells. Left panels (Panels A, C, E, G) show a representative Western blot analysis of EGFR Y1068 phosphorylation in BON cells treated with EGF (16 nM) (Panel A), Bn-analogue
(1 μM) (Panel C) or NT (1 μM) (Panel G), at the indicated times. This experiment is representative of 4 others. The right panels (Panels B, D, F, H) show the results of a densitometric
analysis of results of experiments shown in the accompanying left panel. Shown are mean± SEM of EGFR Y1068 phosphorylation induced by EGF (Panel B), Bn-analogue (Panel D) or
NT (Panel H) treatments. Results are the mean±SEM of 4 separate experiments.
578 A. Di Florio et al. / Biochimica et Biophysica Acta 1833 (2013) 573–582A number of our ﬁndings support the conclusion that various GI
hormones/neurotransmitters, acting through their GPCRs, are able
to stimulate foregut NET/PET cell line's proliferation and that it ismediated in large part by transactivating EGFR. First, using two differ-
ent experimental approaches assessing cell growth, an MTT assay and
assessment of [3H]-thymidine intake, we found that NT, a bombesin
Fig. 4. Effect of Src inhibition on EGFR-transactivation by Bn-analogue and NT in BON cells. (A) Representative Western blot analysis of EGFR Y1068 phosphorylation of BON cells
treated with Bn-analogue (1 μM) or NT (1 μM) for 1 h, with or without the Src inhibitor PP2, (10 μM) or its inactive related peptide, PP3 (10 μM). This result is representative
of 4 others. (B, C) Densitometric analysis of the EGFR phosphorylation, induced by Bn-analogue (B) or NT (C), shown in panel A. Results are expressed as the mean±SEM of 4 ex-
periments. **pb0.01 vs. stimulant alone.
579A. Di Florio et al. / Biochimica et Biophysica Acta 1833 (2013) 573–582receptor agonist (Bn-analogue), PACAP, bradykinin, as well as TGFα
and EGF, were all able to stimulate BON cell growth, as well as in
QGP-1 cells. Second, pre-treatment with the EGFR tyrosine kinase in-
hibitor, AG1478, blocked the increase of cell growth induced by the GI
hormones in both growth assays and in both the cell lines, supporting
the conclusion that the activation of EGFR is an important step in me-
diating their growth effect. Third, we demonstrated directly that the
GI hormones/neurotransmitters inducing growth activate the EGFR,
inducing the activation of downstream signaling cascades [15], by de-
termining, with Western blotting, the generation of the Y1068 phos-
phorylated form of EGFR, which has been shown to correlate withFig. 5. The effect of PKC inhibition or inhibition of metalloproteinases (MMPs) on EGFR-tran
blot analysis of EGFR Y1068 phosphorylation of BON cells treated with Bn-analogue (1 μM) (A
inhibitor, GM 6001. These experiments are representative of 3 different experiments. (B, D
ylation, induced by Bn-analogue (B) and NT (D), as shown in panels A and C. Results are ththe activation of EGFR [25]. Fourth, the Y1068EGFR phosphorylation
induced by NT or Bn-analogue, as well as that induced by EGF, was
prevented by pre-treatment with the EGFR tyrosine kinase inhibitor,
AG1478, under similar conditions that it inhibited BON cells growth
by these agents. Moreover, these results were conﬁrmed in two
other foregut NET/PET cell lines, QGP-1 and Rin-14B. Neurotensin
has been previously demonstrated to stimulate cell growth in pros-
tate cancer cells [23,47] and in pancreatic adenocarcinoma cells
[48]; bombesin [21], as well as NMB [19], stimulate cell proliferation
in non-small-cancer lung cells and HNSCC [37]. and bradykinin stim-
ulates growth of HNSCC through its B2 receptor [32]. Our results aresactivation induced by Bn-analogue or NT, in BON cells. (A, C) Representative Western
) or NT (1 μM) (C) for 1 h, with or without the PKC inhibitor, GF 109203X or the MMP
) Densitometric analysis of the effect of inhibition of PKC or MMP, on EGFR phosphor-
e mean±SEM of 3 experiments. **pb0.01; *pb0.05 vs. stimulant alone.
Fig. 6. Effect of reactive oxygen species (ROS) inhibition on EGFR-transactivation induced by Bn-analogue or NT, in BON cells. (A, C) Representative Western blot analysis of EGFR
Y1068 phosphorylation of BON cells treated with Bn-analogue (1 μM) (A) or NT (1 μM) (C) for 1 h, with or without the ROS production inhibitors, N-acetylcysteine (NAC) or Tiron.
These experiments are representative of 3 different experiments. (B, D) Densitometric analysis of the effect of inhibition of PKC or MMP, on EGFR phosphorylation, induced by
Bn-analogue (B) and NT (D), as shown in panels A and C. Results are the mean±SEM of 3 experiments. *pb0.05 vs. stimulant alone.
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stimulate growth in BON cells and that EGF can stimulate growth
of both KRJ-I cells and BON cells [13]. Similarly in various non-
endocrine tumors, AG1478 or other EGFR inhibitors [PD153035
or geﬁtinib] are able to inhibit cell growth stimulated by various GI
hormones/neurotransmitters [19,21,23,33,47,48] suggesting their
growth stimulation is at least partially mediated by transactivation
of the EGF receptor. In contrast to results in neuroblastoma tumors
and other non-endocrine tumors [49], we found no effect of galanin
on growth of BON cells, nor did we ﬁnd that CCK/gastrin receptors
stimulate BON cells growth, as reported in other Foregut NETs/PETs
[13].
Our studies demonstrated that the activation of EGFR by GI
hormones/neurotransmitters has important similarities and differences
from that of the growth factor, EGF in BON cells and in other tissues.
The action of EGF and the GI hormones (neurotensin and the bombesin
agonist analogue) differed in their kinetics of EGFR activation. Spe-
ciﬁcally, EGF-induced Y1068EGFR tyrosine phosphorylation was very
rapid (peak at 2 min) followed by a rapid decline whereas, Y1068EGFR
tyrosine phosphorylation induced by either the Bn-analogue or
NT was slower with a peak at 60 min, followed by a slight decrease.
These results differ from studies in non-endocrine tumors where
bombesin receptor agonists in HNSCC [22] and in non-small cancer
lung cells [19–21] cause rapid EGFR tyrosine phosphorylation. In
contrast, the delayed time course for neurotensin stimulation of
EGFR tyrosine phosphorylation, in BON cells, is similar to that
reported in prostate cancer cells [23]. The rapid kinetics of EGFR
tyrosine phosphorylation we observed in BON cells with EGF was
also observed in non-transformed human ﬁbroblasts cells [50].
However, it differed from that reported in HNSCC studies, in
which EGF-stimulated EGFR tyrosine phosphorylation showed a
slower kinetic [23,51]. Moreover, EGFR phosphorylation inducedby a bombesin receptor agonist and neurotensin in BON cells was
dose-dependent, with an EC50 in the nanomolar range, similar to the
ability of NT to stimulate EGFR tyrosine phosphorylation in the prostate
cancer cell line, PC3 [47] and of bombesin receptor agonists in non-
small lung cancer cells [21]. These results demonstrated that the
kinetics/stoichiometry of GI hormones/neurotransmitters and growth
factors stimulation of EGFR-transactivation can vary in different cells,
raising the possibility that different mechanisms of activation may be
involved.
Two principal mechanisms play important roles in mediating
EGFR-transactivation by GPCRs: a ligand-dependent mechanism, in-
volving the generation through matrix metalloproteinases (MMPs)
of an EGF-like ligand or a ligand-independent mechanism, that in-
volves the activation of EGFR by the generation of intracellular signals
from activation of the GPCR [16]. A number of our results support
the conclusion that both mechanisms are important in the GPCR-
mediated EGFR-transactivation in BON cells. This conclusion was
supported by the ﬁnding that Y1068EGFR phosphorylation induced
by NT and Bn-analogue in BON cells is inhibited 60–70%, but not
completely, by the pre-treatment with GM6001, a broad spectrum
MMP inhibitor suggesting the ligand-dependent mechanism plays a
particularly important role. This result is similar to those obtained
for bombesin-related peptides, in non-small cancer lung cells and
HNSCC [19,21,22], but it is different from the effect of endothelin-1
in non-transformed ﬁbroblasts and in prostate cancer cells, in which
the inhibition of MMPs completely block EGFR-transactivation [52].
In various non-endocrine cells, transactivation of the EGFR, in
some cases by various GPCRs, requires activation of protein kinase C
(PKC), activation of Src kinases and the generation of reactive oxygen
species (ROS) [17,19–21,48,53]. Activation of receptors for PACAP, NT,
bradykinin and bombesin are all known to activate PKCs in various
cells [17,47,54]. Our results are consistent with the conclusion that
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of NT or Bn receptors is mediated by both PKC-dependent and
PKC-independent mechanisms. This conclusion is supported by our
ﬁnding that after pre-incubation with the broad spectrum PKC inhib-
itor GF109203X, both NT and the bombesin receptor analog activation
of stimulation of Y1068 EGFR tyrosine phosphorylation is markedly
reduced (70–80%), but not completely inhibited. Similar results
are found in some non-endocrine cancer cells, such as for NT- and
bombesin-stimulated transactivation of EGFR in prostate cancer
cells [47] and in non-small cancer lung cells [21] is through a
PKC-mediated mechanism [16]. Our results also demonstrate that ac-
tivation of Src kinases is important in mediating EGFR-transactivation
in BON cells, because we found that EGFR activation induced by NT or
the Bn-analogue, is completely inhibited by the speciﬁc Src kinase in-
hibitor, PP2, but not by a inactive related compound, PP3. This result
is consistent with ﬁndings obtained for bombesin-related peptides in
non-small cancer lung cells [19,21], NT in prostate cancer cells and
endothelin and angiotensin in smooth muscle cells [23,26]. Reactive
oxygen species (ROS) are products of normal metabolism and patho-
logical processes that can have numerous intracellular signaling ef-
fects involved in different far ranging cellular processes including
regulation of intracellular calcium, inhibition of protein function,
growth effects and promoting apoptosis [16,19]. We have found
that the generation of ROS is required for transactivation of EGFR in-
duced by NT or the Bn-analogue in BON cells, since by treating BON
cells either with the ROS scavenger Tiron or the antioxidant
N-acetylcysteine, the phosphorylation of Y1068 of EGFR was inhibited.
Findings in a number of non-endocrine tissues are consistent with
these results with angiotensin II and endothelin EGFR-induced
transactivation, in vascular smooth muscle cells, urotensin EGFR
transactivation in renal tubular cells [53] also shown to be redox sen-
sitive [26], as well as bombesin related peptides and PACAP induced
EGFR-transactivation, in non-small cancer lung cells [17,19,21].
In conclusion our study demonstrates that a number of gastrointes-
tinal homones/neurotransmitters have growth effects on Foregut NETs/
PETs and for the ﬁrst time demonstrates that these growth effects are
highly dependent on transactivation of the EGF receptor. Mechanistic
studies show the EGFR-transactivation is partially dependent on the ac-
tivation of PKC, Src kinases, matrix melloproteinases and the genera-
tion of oxygen free radicals. Because NETs of the gastrointestinal
system frequently possess EGF receptors as well as receptors for vari-
ous GI hormones/neurotransmitters [9–14,24,24], these ﬁndings raise
the possibility that the inhibition of this transactivation could be a
novel method of treating these tumors. This conclusion is supported
by clinical ﬁndings in a phase II trial of the EGFR inhibitor, Geﬁtinib
in patients with progressive metastatic NETs, has shown stabilization
of the tumors [3]. Furthermore, the combination of geﬁtinib combined
with a receptor antagonist for the bombesin receptor which
transactivates the EGFR, have a potentiated cytotoxic effect on lung
cancer cells, head/neck squamous cancer cells and prostate cancer
cells [19,20,31,55–57].
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